Evidence map›Paper›PMID 40852797›Full record

ArticleAngewandte Chemie (International ed. in English)2025

Molecular Afterglow of Lophine-Based Luminophore and Its Imaging Applications.

Jun Yang, Yusheng Yang, Huizhe Wang, Steven H Liang, Chongzhao Ran

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jun YangAthinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Boston, Massachusetts, 02129, USA.
Yusheng YangArclight Quantum Computing Inc, Beijing, 100191, China.
Huizhe WangAthinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Boston, Massachusetts, 02129, USA.
Steven H LiangDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia, 30322, USA.
Chongzhao RanAthinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Boston, Massachusetts, 02129, USA.ORCID 0000-0002-3892-4108

Funding

Development of sensitive PET tracers of pan-Amyloid-beta species for Alzheimer's diseaseR01AG085562 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Chongzhao Ran · 2024 to 2026
$2.5M
Molecular Chemiluminescence Probes for Imaging of Amyloid beta in Animal ModelsR01AG083759 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Chongzhao Ran, Can Martin Zhang · 2024 to 2026
$2.5M
Near infrared fluorescence imaging of reactive oxygen species in Alzheimer's diseaseR01AG055413 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI RAN, CHONGZHAO · 2018 to 2022
$2.1M
Upgrade and replacement of IVIS Spectrum imaging systemS10OD028609 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI RAN, CHONGZHAO · 2020 to 2020
$600k
Differentiating Abeta40/42 in plaques with small molecule fluorescent probesR21AG078749 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI RAN, CHONGZHAO · 2022 to 2022
$459k
Near infrared Fluorescence Ocular Imaging of Soluble Amyloid Beta SpeciesR21AG059134 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI RAN, CHONGZHAO · 2018 to 2019
$459k
Epitope alteration for detecting auto-antibodies of beta-amyloid in serumR21AG080222 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI RAN, CHONGZHAO · 2023 to 2023
$459k
NIA NIH HHS R01 AG083759NIA NIH HHS R01 AG085562NIA NIH HHS R21 AG059134NIA NIH HHS R21 AG078749NIA NIH HHS R21 AG080222NIH HHS R01AG055413NIH HHS R01AG085562NIH HHS R21AG059134NIH HHS R21AG078749NIH HHS S10 OD028609NIH HHS S10OD028609
6 · The paper itself

Abstract

Lophine, the first chemiluminescent compound discovered in history, has rarely been applied for in vivo imaging since its discovery in 1877. In this report, we demonstrate that lophine's chemiluminescence emission could be significantly enhanced by caging the imidazole moiety via molecular afterglow mechanism. Notably, our study revealed a rare superoxide anion-mediated luminescence. Our novel probes JIMI-11 and JIMI-12 could be used for in vivo mouse imaging. Compared to its uncaged form JIMI-6, JIMI-11 exhibited a significant enhancement (126-fold) in vitro and a 190-fold higher emission signal in vivo. JIMI-11 selectively accumulates in white adipose tissues (WAT) and can be used to monitor changes in WAT mass in a mouse model of type-1 diabetes. Additionally, it can assess the therapeutic effects of Semaglutide in a mouse model of diet-induced obesity. Lastly, we designed JIMI-12 with a reactive oxygen/nitrogen species (ROS/RNS) responsive moiety as the caging group and demonstrated its utility for in vivo imaging of ROS in a lipopolysaccharide (LPS)-induced inflammatory mouse model. Our studies suggest that re-designing lophine-based probes could unlock their potential for both in vitro and in vivo applications. The ability to switch from chemiluminescence to molecular afterglow introduces a novel approach to designing imaging probes.

Indexed as

Luminescent AgentsAnimalsImidazolesMiceOptical ImagingReactive Oxygen SpeciesImidazolesLuminescent AgentsReactive Oxygen SpeciesAdipose tissue imagingAfterglow imagingLophineMolecular lightSuperoxide anion

Identifiers

PMID40852797
PMCPMC12924693

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.